Retired Nurse Judy Aiken Highlighted Her Lived-Experience With High Drug Prices, Shared How The Out-of-Pocket Cap And Medicare Negotiation Feels Like A “Lifeline”
WASHINGTON, D.C. — Judy Aiken, a retired nurse and P4ADNOW patient advocate from Portland, Maine testified today before the Senate Finance Committee at a hearing titled “Lower Health Care Costs for Americans: Understanding the Benefits of the Inflation Reduction Act” about the relief being delivered to patients via the drug price reforms in the historic Inflation Reduction Act.
Judy, who has battled psoriatic arthritis and psoriasis for over four decades, emphasized how the drug price law has already reined in her soaring out-of-pocket costs; Prior to the passage of the Inflation Reduction Act, Judy paid more than $9,000 out-of-pocket in a single year for Enbrel alone.The Inflation Reduction Act’s out-of-pocket cap reduced her prescription drug costs to about $3,300 in 2024 — nearly a third of what she paid last year. In 2025, her annual out-of-pocket expenses will be capped at $2,000.Judy also highlighted the additional relief she will experience beginning in 2026 thanks to the historic Medicare negotiation program, which for the first time in two decades allows Medicare to negotiate some of the costliest and most common drugs covered by Medicare; Enbrel, one of her prescribed medications, is among the first 10 drugs selected for negotiation.Starting in 2026, Enbrel’s negotiated price will be $2,355 per month, a 67 percent reduction from its current monthly list price.As someone who has worked as a nurse for four decades, Judy knows firsthand the importance of adhering to a consistent medication regimen. “But the cruel irony is that I’ve sometimes found myself skipping doses, unable to follow my own advice due to the prohibitive cost,” Judy shared in her testimony.
But now, the drug price reforms are lessening the financial strain of high-cost prescription drugs for millions of patients like Judy. She also shared that, “The impact of these changes cannot be overstated. My husband and I can now breathe easier. We’re addressing those long-postponed home repairs. And we may even be able to take a trip. But most importantly, I no longer have to choose between my health and our financial stability.
This is the real, tangible impact of the Inflation Reduction Act. It’s not just about numbers on a page or political talking points. It’s about people – seniors like me, who have worked hard their whole lives, and who can now afford the medications we need to live healthier, more productive lives with dignity.”
FIND JUDY’S FULL TESTIMONY BELOW:
Chairman Wyden, Ranking Member Crapo, Committee Members
Thank you for inviting me to share my story today.
I’m Judy Aiken – a 70-year-old retired nurse, born and raised in Portland, Maine, where I live with my husband of 47 years.
I have been battling psoriatic arthritis and psoriasis for over four decades. These conditions have taken a heavy toll on my body, but the financial strain of the medications I need has been equally challenging.
Seventeen years ago, my doctor prescribed Enbrel to manage my condition. It’s been a lifeline, but one with a staggering price tag. Since its introduction 26 years ago, Enbrel’s price has skyrocketed by more than 700 percent. Today, it is priced at $7,106 for a 30-day supply.
Last year alone, I paid over $9,000 out-of-pocket just for this one medication. The cost was overwhelming. As a nurse, I spent years counseling patients on the importance of taking their medications consistently. But the cruel irony is that I’ve sometimes found myself skipping doses, unable to follow my own advice due to the prohibitive cost.
Every trip to the pharmacy was a source of anxiety. How much would it cost this time? Could we afford it? What else would we have to sacrifice? My husband and I were constantly juggling our budget – we postponed home repairs and stopped going out to eat.
Then came the Inflation Reduction Act, and with it, a glimmer of hope.
This year, I braced for another 12 months of expensive pharmacy visits. But after paying $2,150 in January and $1,141 in February, a real shock came in March. I went to pick up my prescription and discovered my out-of-pocket cost would be $0 for the rest of the year. I nearly cried at the pharmacy counter. Even after advocating for the passage of the drug price reforms in the Inflation Reduction Act, I was skeptical it would actually benefit me. But it has, and this year my out-of-pocket costs have been capped at $3,300.
And there’s more relief on the horizon. Next year, the out-of-pocket limit will drop further, capping at $2,000 for everyone on Medicare Part D. For patients like me who rely on expensive medications, this is truly life-changing.
But that’s not the only IRA provision that I will benefit from. Enbrel was one of the first 10 drugs selected for Medicare price negotiation. After the inaugural round of negotiated prices were released in August, I learned that beginning in 2026, Enbrel’s price will be reduced to $2,355 per month – a 67 percent reduction.
These lower negotiated prices come after decades of advocacy from patients like me and represent the first time in Medicare’s history that the program has directly negotiated drug prices with pharmaceutical corporations. These 10 drugs cover treatments for common conditions such as diabetes, heart disease, and blood clots, and the roughly nine million patients on Medicare who take at least one of these drugs are projected to save $1.5 billion out of pocket in 2026 alone.
It’s important to note that the out-of-pocket savings are made possible by lowering the prices. We cannot do one without the other.
The impact of these changes cannot be overstated. My husband and I can now breathe easier. We’re addressing those long-postponed home repairs. And we may even be able to take a trip. But most importantly, I no longer have to choose between my health and our financial stability.
This is the real, tangible impact of the Inflation Reduction Act. It’s not just about numbers on a page or political talking points. It’s about people – seniors like me, who have worked hard their whole lives, and who can now afford the medications we need to live healthier, more productive lives with dignity.
The IRA demonstrates that when our elected leaders take action, real change is possible. While there’s still work to be done to make prescription drugs affordable for all Americans, this is a huge step in the right direction.
I urge you to continue supporting and strengthening these life-saving reforms. They are making a real difference in the lives of millions of American patients.
Thank you for your time and attention to this crucial issue. I look forward to answering your questions.
###
Patients for Affordable Drugs Now, is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more visit PatientsForAffordableDrugsNOW.org.
Retired Nurse Judy Aiken Highlighted Her Lived-Experience With High Drug Prices, Shared How The Out-of-Pocket Cap And Medicare Negotiation Feels Like A “Lifeline”
WASHINGTON, D.C. — Judy Aiken, a retired nurse and P4ADNOW patient advocate from Portland, Maine testified today before the Senate Finance Committee at a hearing titled “Lower Health Care Costs for Americans: Understanding the Benefits of the Inflation Reduction Act” about the relief being delivered to patients via the drug price reforms in the historic Inflation Reduction Act. Judy, who has battled psoriatic arthritis and psoriasis for over four decades, emphasized how the drug price law has already reined in her soaring out-of-pocket costs;Prior to the passage of the Inflation Reduction Act, Judy paid more than $9,000 out-of-pocket in a single year for Enbrel alone.The Inflation Reduction Act’s out-of-pocket cap reduced her prescription drug costs to about $3,300 in 2024 — nearly a third of what she paid last year.In 2025, her annual out-of-pocket expenses will be capped at $2,000.Judy also highlighted the additional relief she will experience beginning in 2026 thanks to the historic Medicare negotiation program, which for the first time in two decades allows Medicare to negotiate some of the costliest and most common drugs covered by Medicare; Enbrel, one of her prescribed medications, is among the first 10 drugs selected for negotiation.Starting in 2026, Enbrel’s negotiated price will be $2,355 per month, a 67 percent reduction from its current monthly list price.As someone who has worked as a nurse for four decades, Judy knows firsthand the importance of adhering to a consistent medication regimen. “But the cruel irony is that I’ve sometimes found myself skipping doses, unable to follow my own advice due to the prohibitive cost,” Judy shared in her testimony. But now, the drug price reforms are lessening the financial strain of high-cost prescription drugs for millions of patients like Judy. She also shared that, “The impact of these changes cannot be overstated. My husband and I can now breathe easier. We’re addressing those long-postponed home repairs. And we may even be able to take a trip. But most importantly, I no longer have to choose between my health and our financial stability. This is the real, tangible impact of the Inflation Reduction Act. It’s not just about numbers on a page or political talking points. It’s about people – seniors like me, who have worked hard their whole lives, and who can now afford the medications we need to live healthier, more productive lives with dignity.” |
FIND JUDY’S FULL TESTIMONY BELOW: Chairman Wyden, Ranking Member Crapo, Committee Members Thank you for inviting me to share my story today. I’m Judy Aiken – a 70-year-old retired nurse, born and raised in Portland, Maine, where I live with my husband of 47 years. I have been battling psoriatic arthritis and psoriasis for over four decades. These conditions have taken a heavy toll on my body, but the financial strain of the medications I need has been equally challenging. Seventeen years ago, my doctor prescribed Enbrel to manage my condition. It’s been a lifeline, but one with a staggering price tag. Since its introduction 26 years ago, Enbrel’s price has skyrocketed by more than 700 percent. Today, it is priced at $7,106 for a 30-day supply. Last year alone, I paid over $9,000 out-of-pocket just for this one medication. The cost was overwhelming. As a nurse, I spent years counseling patients on the importance of taking their medications consistently. But the cruel irony is that I’ve sometimes found myself skipping doses, unable to follow my own advice due to the prohibitive cost. Every trip to the pharmacy was a source of anxiety. How much would it cost this time? Could we afford it? What else would we have to sacrifice? My husband and I were constantly juggling our budget – we postponed home repairs and stopped going out to eat. Then came the Inflation Reduction Act, and with it, a glimmer of hope. This year, I braced for another 12 months of expensive pharmacy visits. But after paying $2,150 in January and $1,141 in February, a real shock came in March. I went to pick up my prescription and discovered my out-of-pocket cost would be $0 for the rest of the year. I nearly cried at the pharmacy counter. Even after advocating for the passage of the drug price reforms in the Inflation Reduction Act, I was skeptical it would actually benefit me. But it has, and this year my out-of-pocket costs have been capped at $3,300. And there’s more relief on the horizon. Next year, the out-of-pocket limit will drop further, capping at $2,000 for everyone on Medicare Part D. For patients like me who rely on expensive medications, this is truly life-changing. But that’s not the only IRA provision that I will benefit from. Enbrel was one of the first 10 drugs selected for Medicare price negotiation. After the inaugural round of negotiated prices were released in August, I learned that beginning in 2026, Enbrel’s price will be reduced to $2,355 per month – a 67 percent reduction. These lower negotiated prices come after decades of advocacy from patients like me and represent the first time in Medicare’s history that the program has directly negotiated drug prices with pharmaceutical corporations. These 10 drugs cover treatments for common conditions such as diabetes, heart disease, and blood clots, and the roughly nine million patients on Medicare who take at least one of these drugs are projected to save $1.5 billion out of pocket in 2026 alone. It’s important to note that the out-of-pocket savings are made possible by lowering the prices. We cannot do one without the other. The impact of these changes cannot be overstated. My husband and I can now breathe easier. We’re addressing those long-postponed home repairs. And we may even be able to take a trip. But most importantly, I no longer have to choose between my health and our financial stability. This is the real, tangible impact of the Inflation Reduction Act. It’s not just about numbers on a page or political talking points. It’s about people – seniors like me, who have worked hard their whole lives, and who can now afford the medications we need to live healthier, more productive lives with dignity. The IRA demonstrates that when our elected leaders take action, real change is possible. While there’s still work to be done to make prescription drugs affordable for all Americans, this is a huge step in the right direction. I urge you to continue supporting and strengthening these life-saving reforms. They are making a real difference in the lives of millions of American patients. Thank you for your time and attention to this crucial issue. I look forward to answering your questions. |
### Patients for Affordable Drugs Now, is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more visit PatientsForAffordableDrugsNOW.org. |
Patients For Affordable Drugs NOW Steps Up Push For Competition to Lower Drug Prices Including Six-Figure Ad Campaign
Ads, Letters, Lobby Day in Coming Weeks Urge Congress To Pass Bills To Boost Competition and Reform Patent Law To Lower Drug Prices
WASHINGTON, D.C. — Patients For Affordable Drugs Now (P4ADNow) has launched a six-figure ad campaign to urge Congress to pass a package of bipartisan bills that crack down on the drug industry’s anti-competitive practices in order to lower prescription drug prices for patients. The ads are the latest effort in P4ADNow’s continued “Push For Competition To Lower Drug Prices”, focusing on reforming patent laws and closing regulatory loopholes to promote generic and biosimilar competition and curbing anti-competitive tactics that allow drug companies to keep prices high by extending unwarranted monopolies on life-saving medications.
The campaign, which includes a combination of video, audio, and static ads, are running on digital and social media platforms and features Lisa McRipley, a patient with multiple sclerosis (MS), whose vital medications have a price of nearly $7,500 each month, and Jacqueline Garibay, a patient who lives with ankylosing spondylitis, an autoimmune disorder, and has had to go without her medication at times because of the $6,000 per month cost. View Lisa’s ad here.
“Patients like Lisa and Jacqueline are struggling to afford the medications they depend on because drug companies have been manipulating the patent system for decades to maintain their monopoly power and keep prices high,” said Merith Basey, Executive Director of Patients For Affordable Drugs Now. “Legislators can act during this Congress to pass this package of bipartisan legislation to increase competition and curb pharma’s abusive practices to ensure that affordable generics and biosimilars can enter the market, lower prices, and begin to bring overdue relief to patients.
“Lowering drug prices isn’t just a policy priority – it’s a public mandate. Patients, consumers, and taxpayers are calling for action – with 9 in 10 voters saying Congress should prioritize policies to lower drug prices. Congress has the power and the bipartisan support to pass these competition bills and make medications more affordable for all Americans. It’s high time we curb drug companies’ abusive practices – Congress can get it done this year.”
Anti-competitive practices in the pharmaceutical industry including patent thicketing, pay-for-delay agreements, and product hopping, have led to inflated drug prices, costing patients and taxpayers billions. When generic or biosimilar versions enter the market, prices can fall dramatically – by nearly 40 percent when there is one additional competitor and 85-95 percent when there are six or more competitors.
In 2023, the Senate Judiciary Committee unanimously passed several bipartisan bills to improve competition in the prescription drug market and in July this year, the Senate unanimously passed the amended Affordable Prescriptions for Patients Act of 2023 (S.150) – which targeted the pharmaceutical industry’s use of patent thickets.
The House now has the chance to build on that momentum. By advancing additional bipartisan competition bills, including H.R. 9070 and H.R. 6986, Congress can bring relief to patients like Lisa, Jacqueline, and millions of others burdened by excessive drug costs. These bills are projected to save taxpayers more than $4.5 billion over the next ten years.
BACKGROUND
###
Patients for Affordable Drugs NOW, is the only national, bipartisan patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNOW does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more visit PatientsForAffordableDrugsNOW.org.
P4ADNow Applauds Unanimous Senate Passage Of Bill To Curb Patent Thicketing, Urges Swift House Action To Lower Drug Prices
Affordable Prescriptions for Patients Act of 2023 Will Increase Competition And Drive Down Prices Of Rx Drugs For All Americans
WASHINGTON, D.C. — In a major step forward for patients and consumers, the U.S. Senate has unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), to curb abuses of the patent system by tackling Big Pharma’s patent thicketing of biologics to increase competition in the drug market and lower prescription drug prices for millions of Americans of all ages.
Patients For Affordable Drugs Now (P4ADNow) hailed the unanimous Senate passage of S-150 as significant progress toward ensuring all Americans can access the drugs they need at prices they can afford. The organization launched its push for competition to lower drug prices in July 2023 by uplifting the voices of thousands of patients who are calling for reforms from Congress to curb drug companies patent abuses that extend their monopolies to block generic and biosimilar competition.
“Today’s Senate action is another important victory for patients that can pave the way for House action and full Congressional passage of this bipartisan bill this year,”said Merith Basey, Executive Director of Patients For Affordable Drugs Now. “This bill begins to strike at the heart of Big Pharma’s patent abuses that have kept U.S. drug prices artificially high for far too long. The overwhelming bipartisan support for this reform through unanimous consent proves that when patients demand change, our legislators listen. We are grateful to the tireless advocacy from thousands of patients, their families, and allies as well asSenators Cornyn and Blumenthal for their leadership and Senators from both parties who stood against pharmaceutical industry pressure and voted to put patients first.”
“Today’s Senate action has brought us closer to tangible savings for all Americans at the pharmacy counter. And now our message to the House is clear: let’s finish the job. We are continuing to mobilize patient advocates to ensure S-150 becomes law. Americans pay the highest prices in the world for their medications and are counting on swift, decisive action by the House of Representatives to lower their drug costs.”
Today’s bipartisan victory in the Senate was only achieved because of patient advocates who shared their lived experiences, making it possible to reach policymakers in Washington. Patients sent over 27,000 letters and made over 30,000 calls to Congressional offices demanding legislators to pass a package of bills to rein in pharmaceutical patent abuses and ensure patients get the drugs they need at prices they can afford.
“Accessing the medications that I need, at the quantities that I need them, could become easier and more affordable if more competition was allowed to enter the market,” said Jacquie Persson, a patient advocate from Waterloo, Iowa who struggles to afford the medication she needs to manage her Crohn’s disease. “I wouldn’t have to ration or stress about prior authorization approvals if I had access to more affordable options with the same result.”
P4ADNow extends its gratitude to the lead sponsors and key supporters of this crucial legislation, including Senators Cornyn and Blumenthal for their leadership on the Affordable Prescriptions for Patients Act of 2023. We also commend Senators Klobuchar and Grassley for their tireless efforts in pushing for drug pricing reform. Additionally, we recognize Senator Durbin for his continued advocacy and for holding the May Senate Judiciary Committee hearing on Big Pharma’s anti-competitive tactics and Senator Graham for his vocal support during the hearing where he emphasized the need to bring these bills to the floor for a vote.
BACKGROUND
###
Patients for Affordable Drugs NOW, is the only national, bipartisan patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNOW does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more visit PatientsForAffordableDrugsNOW.org.
Patients For Affordable Drugs Now Responds To Federal Trade Commission’s Scathing Report On Pharmacy Benefit Managers
FTC Confirms PBMs Inflate Drug Costs, Harm Patients
WASHINGTON, D.C. — Patients For Affordable Drugs Now (P4ADNow) issued the following statement in response to the Federal Trade Commission’s (FTC) bipartisan interim staff report on Pharmacy Benefit Managers (PBMs):
“It will come as no surprise that the FTC’s report confirms what patients have long suspected: the largest PBMs wield significant control over which drugs are available for patients and at what price,” said Merith Basey, Executive Director of Patients For Affordable Drugs Now. “While PBMs were designed to benefit patients, in reality, they exploit their power to inflate drug costs. We commend the FTC for its report and ongoing investigation into these harmful practices.”
“Make no mistake, while PBM reform is urgently needed to bring true transparency to the PBM black box to lower drug prices for patients, Big Pharma should not be excluded from the narrative. Nearly 1 in 3 Americans cannot afford their prescription drugs largely due to drug companies’ abuses of the patent system and their ability to set and raise drug prices with impunity. P4ADNow remains committed to system-changing reforms that prioritize patients over Big Pharma and PBMs profits.”
Key findings from the report reveal:
P4ADNow supports reforms aimed at increasing transparency and curbing anti-competitive practices of PBMs, including key provisions in the Modernizing and Ensuring PBM Accountability Act (S. 2973) for its transparency requirements, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (S 3430) for its reporting provisions, as well as the Lower Cost, More Transparency Act (H.R. 5378), aiming for reforms that prioritize patients and consumers.
###
Patients for Affordable Drugs NOW, is the only national, bipartisan patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNOW does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more visit PatientsForAffordableDrugsNOW.org.
Patients For Affordable Drugs NOW Founder and Cancer Patient David Mitchell Testifies Before Senate Judiciary Committee On Need For Patent Reforms To Lower Drug Prices
Calls For Closing Loopholes Exploited By Drug Companies, Restoring Patent System’s Intent To Spur Innovation Not To Block Competition
WASHINGTON, D.C. — David Mitchell, founder of Patients For Affordable Drugs NOW and a patient with a rare incurable cancer, will testify at 10 AM today before the United States Senate Judiciary Committee about the anticompetitive tactics used by pharmaceutical companies to extend drug monopolies and keep prices high for patients in the United States. Watch the testimony for the “Ensuring Affordable & Accessible Medications: Examining Competition in the Prescription Drug Market” hearing.
Mitchell will emphasize the urgent need for bipartisan reforms that strike the right balance between ensuring patents reward true innovation while facilitating timely competition to make prescription drugs affordable for people whose lives depend on them.
In his testimony submitted to the committee, Mitchell highlighted how pharmaceutical companies manipulate the patent system to extend their monopolies and block lower-cost generic and biosimilar competition from entering the market, rather than incentivizing genuine innovation as the laws intend. He pointed to strategies like product hopping, patent thicketing, pay-for-delay deals, and misuse of the Food and Drug Administration (FDA) citizen petitions as prime examples of Big Pharma’s tactics that reduce competition and keep prices higher for longer. Mitchell voiced strong support for a package of bipartisan bills in the Senate that rein in these abuses and close loopholes that drugmakers exploit at the expense of patients. By tackling anticompetitive practices, the reforms would realign incentives to spur innovation while better facilitating timely market entry to drive down prices consistent with the will of Congress.
As someone battling an incurable blood cancer, Mitchell knows firsthand the importance of innovation for developing new, life-extending treatments. “I care deeply about innovation and new drug development. My life depends on it. Without innovation, I will die sooner than I hope to,” he shared in his testimony. “That is not a plea for sympathy – it’s just an unfortunate fact.”
His testimony also highlighted the stories of other patients struggling with high drug costs, such as Judy from Maine who was initially skeptical but relieved when her Enbrel copay went from over $2,000 to $0 thanks to the Inflation Reduction Act, and Samantha from West Virginia who has been in recovery for 10 years but has to pay $800 for a 90-day supply of Suboxone for opioid addiction treatment. His testimony also shared that Beatel from Minnesota saw the price for 40mg of cholesterol drug Tricor skyrocket to $1,800 per month after joining Medicare at 65 but found the pharmacist could provide the same 80mg dose using 160mg tablets for just $40 since that larger dose was off-patent. And lastly, John from Baltimore, who is also battling multiple myeloma, pays $990 per pill for the cancer drug Revlimid that his insurer refuses to cover, leaving him feeling “hijacked” and at the mercy of the manufacturer’s assistance program – a situation he says is “scarier than the disease itself.”
Key highlights from the testimony include:
You can find the full written testimony linked HERE.
###
Patients for Affordable Drugs NOW, is the only national, bipartisan patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNOW does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more visit PatientsForAffordableDrugsNOW.org.
In response to President Biden’s comments in his State of the Union address about the historic drug price reforms in the Inflation Reduction Act and the forward-looking proposals he announced to further reduce drug prices, Merith Basey, Executive Director of Patients For Affordable Drugs Now, issued the following statement:
“Tonight, President Biden highlighted the monumental drug price reforms achieved through the Inflation Reduction Act, a cornerstone of his agenda and an issue that is overwhelmingly supported by the American people who are tired of being ripped off by pharmaceutical companies to the detriment of their lives and livelihoods.
“The enactment of the historic drug price reforms, coupled with the President’s proposal to more than double the number of drugs subject to Medicare negotiation and expand cost-saving measures to millions of people on private insurance, would be transformative toward ensuring that everyone in the U.S. can access the drugs they need at prices they can afford.
“This landmark legislation is a testament to the relentless efforts of patients. While we are already witnessing the impact of some of these reforms to lower drug prices, we continue to hear from patients burdened with high drug prices who are desperate for relief. On behalf of patients, we will continue to advocate for policies that protect and expand on the drug price reforms in the Inflation Reduction Act, dismantle Big Pharma’s abuse of the patent system, and make drugs more affordable for all who need them.”
P4ADNow patient advocate, Steven Hadfield, was a guest of First Lady Jill Biden in her box during the State of the Union this evening. Steven, who is 71 and a longtime resident of North Carolina, takes Januvia for his diabetes, which is one of the first 10 drugs selected for Medicare negotiation. He is also living with blood cancer and despite being in his 70s, cannot retire due to the price of his medications. He shared the following statement:
“’For far too long, big drug companies have made a fortune while patients like me live in constant fear, wondering how we’ll pay for our medicine. The Inflation Reduction Act has been a lifeline, reducing my insulin costs from $400 to $35 per month. Medicare’s ability to negotiate lower drug prices offers hope for millions of patients like me. Less expensive drugs would finally allow me to rest more often or hopefully help me transition from working full-time to working part-time. I am honored to be a guest of First Lady Jill Biden during the State of the Union as President Biden advocates for lower drug prices. He understands that drugs don’t work if people can’t afford them.”
BACKGROUND
The historic Inflation Reduction Act is lowering prescription drug prices and reducing out-of-pocket costs for millions of people in this country.
###
Patients for Affordable Drugs Now, the C4 arm of P4AD, is the only national, bipartisan patient advocacy organization focused exclusively on policies to lower drug prices. We help educate and mobilize patients in support of legislation to fix our broken system. P4ADNOW does not accept funding from organizations that profit from the development and distribution of drugs.
Today, the Biden Administration announced proposals to more than double the number of drugs to be negotiated by Medicare and expand the $2,000 cap on out-of-pocket prescription drugs to people on private insurance – extending savings to an additional 189 million people not on Medicare.
The proposal also includes a $2 cost-sharing limit for specific generic drugs such as statins and beta-blockers for people on Medicare Part D, improving access to cell and gene therapies, starting with addressing sickle cell disease, a condition that affects more than 100,000 people in the United States, and extending requirements for drug companies to pay rebates when their price increases exceed the rate of inflation.
Merith Basey, Executive Director of Patients For Affordable Drugs Now, responded to the proposal with the following statement:
“These proposals would expand on the historic progress already being made as a result of the drug price reforms in the Inflation Reduction Act. For two decades, Americans have been held hostage by a system preventing the United States government from negotiating for lower drug prices on behalf of patients. These proposals would build upon hard-won victories and represent another step forward for patients and advocates in our ongoing fight to ensure that every person can get the drugs they need at prices they can afford. As we continue to hear from patients every day who are being forced to make impossible choices between skipping their medication or paying their bills —the urgency of this fight has never been more apparent.”
Americans pay 3-8 times more than other high-income nations for brand-name prescription drugs, and over 90 percent of voters from across the political spectrum said lowering prices should be an important or top priority for Congress. This announcement on the eve of President Biden’s State of the Union address, signals the Biden Administration’s commitment to prioritizing lowering drug prices in the coming year.
###